Ligne de temps

Gabriel Aymé
Ingénieur(e) de Recherche
18 mars 2024
publication

Cryo-EM structures of type IV pili complexed with nanobodies reveal immune escape mechanisms

Lire plus
25 sept. 2023
publication

An original potentiating mechanism revealed by the cryo-EM structures of the human α7 nicotinic receptor in complex with nanobodies.

Lire plus
22 juin 2023
event

Single-Domain Antibodies 2023

Lire plus
25 mai 2023
publication

Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor.

Lire plus
09 mars 2023
publication

Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.

Lire plus
25 oct. 2022
project

Advances in cancer immunotherapy development: VHH-based immune checkpoint inhibitors targeting the receptor ILT4

Lire plus
01 janv. 2022
publication

Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein.

Lire plus
10 avr. 2020
project

CORONABODIES

Lire plus
07 avr. 2020
publication

Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.

Lire plus
16 janv. 2020
project

VenoMATIcs: Toward a Global Management of Venoms and Envenomations: the Pasteur network Translational Approach

Lire plus
13 sept. 2018
publication

A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.

Lire plus
01 avr. 2018
publication

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.

Lire plus
27 févr. 2018
project

Toxins and nanobodies as subtype-specific ligands and allosteric modulators of nicotinic acetylcholine receptors (PTR Nicobinder)

Lire plus
01 sept. 2017
publication

A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.

Lire plus
27 avr. 2017
publication

Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions.

Lire plus
06 oct. 2016
publication

LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Lire plus
17 févr. 2015
team

Ingénierie des Anticorps

Lire plus